Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : Clown-Free Zone... sorry, no clowns allowed -- Ignore unavailable to you. Want to Upgrade?

To: patron_anejo_por_favor who wrote (108135)	6/11/2001 10:42:14 PM
From: jjetstream	Respond to of 436258

Agreed, and, OH MY, Affymetrix, genechip revs are down..... Affymetrix sees weak second-quarter revenues (UPDATE: adds details in para. 4-7, stock price in para. 8) SANTA CLARA, Calif., June 11 (Reuters) - Genetic technology company Affymetrix, Inc., (NasdaqNM:AFFX - news) said on Monday it projected a shortfall in second-quarter revenues and anticipated to report a net loss, before charges, of between $4 to $7 million due to weak demand for its GeneChip product line. The Santa Clara, California-based company said it expected revenues for the second-quarter to be in the range of $44 million to $50 million, including $3 million to $4 million in revenue from Perlegen Sciences, Inc. The company's GeneChip product arrays are used by scientists to determine the activity of genes. Analysts polled by research firm Thomson Financial/First Call had forecast Affymetrix to record a loss of 2 cents a share for the second quarter. The company said although it was managing expenses, it would not reduce investments in research and development or infrastructure in a manner that would be harmful to its long-term prospects. It said it did not expect further weakness in its overall business, but believed that it could be sporadic for at least the next two to three quarters. ``The nascent state of our market combined with variable economic conditions and rapidly changing dynamics affecting our largest customers have made it challenging to accurately forecast growth,'' Stephen Fodor, Affymetrix chairman and chief executive said in a statement. Affymetrix shares closed on the Nasdaq down 8.41 percent, or $3.76, at $40.95. They have a 52-week trading range of $23.25 to $103.75.